Pulmonary Vascular Disease News

SAN FRANCISCO — Inhaled treprostinil significantly improved persistence, adherence and lowered risk for hospitalization compared with iloprost in patients with pulmonary arterial hypertension, researchers reported.

SAN FRANCISCO — In this Healio video exclusive, Parth Rali, MD, and Belinda Natalia Rivera-Lebron, MD, MS, spotlight catheter-directed therapy for patients with intermediate-risk pulmonary embolism.

SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.

SAN FRANCISCO — In this video exclusive, Belinda Natalia Rivera-Lebron, MD, MS, highlights recent updates in the treatment of pulmonary hypertension.

United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.

Patients with CVD are 40% to 80% more likely to have comorbid obstructive sleep apnea, which in severe cases can cause them to stop breathing hundreds of times a night.

In a new study, improvements in multicomponent endpoints and risk stratification tools based on functional class, 6-minute walk distance and N-terminal pro-B-type natriuretic peptide better predicted pulmonary artery hypertension survival.

May 5 is World PH Day, which aims to raise awareness of pulmonary hypertension and its global impact.

A new study suggests that many patients with pulmonary embolism who present as hemodynamically stable may be in subclinical shock due to low cardiac index.

Transition from nebulized inhaled treprostinil to a dry powder inhaled formulation was safe, well tolerated and led to significant improvements in clinical and patient-reported outcomes in patients with pulmonary arterial hypertension.